Get access

Successful “in-flight” activation of natural killer cells during long-distance shipping

Authors

  • Scott A. Koepsell,

    1. From the Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School; the Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics; and the Departments of Medicine and Pediatrics, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis/Saint Paul, Minnesota; and Tufts Medical Center, Boston, Massachusetts.
    Search for more papers by this author
  • Diane M. Kadidlo,

    1. From the Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School; the Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics; and the Departments of Medicine and Pediatrics, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis/Saint Paul, Minnesota; and Tufts Medical Center, Boston, Massachusetts.
    Search for more papers by this author
  • Susan Fautsch,

    1. From the Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School; the Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics; and the Departments of Medicine and Pediatrics, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis/Saint Paul, Minnesota; and Tufts Medical Center, Boston, Massachusetts.
    Search for more papers by this author
  • Jeffrey McCullough,

    1. From the Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School; the Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics; and the Departments of Medicine and Pediatrics, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis/Saint Paul, Minnesota; and Tufts Medical Center, Boston, Massachusetts.
    Search for more papers by this author
  • Hans Klingemann,

    1. From the Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School; the Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics; and the Departments of Medicine and Pediatrics, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis/Saint Paul, Minnesota; and Tufts Medical Center, Boston, Massachusetts.
    Search for more papers by this author
  • John E. Wagner,

    1. From the Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School; the Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics; and the Departments of Medicine and Pediatrics, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis/Saint Paul, Minnesota; and Tufts Medical Center, Boston, Massachusetts.
    Search for more papers by this author
  • Jeffrey S. Miller,

    1. From the Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School; the Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics; and the Departments of Medicine and Pediatrics, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis/Saint Paul, Minnesota; and Tufts Medical Center, Boston, Massachusetts.
    Search for more papers by this author
  • David H. McKenna Jr

    Corresponding author
    1. From the Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School; the Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics; and the Departments of Medicine and Pediatrics, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis/Saint Paul, Minnesota; and Tufts Medical Center, Boston, Massachusetts.
      David H. McKenna Jr, MD, Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics, 1900 Fitch Avenue, Saint Paul, Minnesota 55108; e-mail: mcken020@umn.edu.
    Search for more papers by this author

  • Supported in part by the National Heart, Lung, and Blood Institute Contract N01-HB-47095 (Production Assistance for Cellular Therapies, or PACT), P01 CA111412 (JSM), and the BMT Research Fund and Children's Cancer Research Fund (JEW, JSM).

David H. McKenna Jr, MD, Clinical Cell Therapy Laboratory, University of Minnesota Medical Center, Molecular and Cellular Therapeutics, 1900 Fitch Avenue, Saint Paul, Minnesota 55108; e-mail: mcken020@umn.edu.

Abstract

BACKGROUND: Natural killer (NK) cells have shown promise in the treatment of malignancy. However, the widespread use of these cells may be limited by both the lack of resources and the expertise needed to manufacture them and the apparent need to use only fresh cells. The NHLBI-sponsored Production Assistance for Cellular Therapies group was established to provide the resources and expertise to carry out cell therapy research, including support of clinical trials. Here we describe the qualification of in transit activation of an NK-cell therapy product in preparation for a Phase I clinical trial at a distant medical center.

STUDY DESIGN AND METHODS: Nonmobilized apheresis mononuclear cell collections were CD3+ cell depleted, placed into culture bags with interleukin (IL)-2, and shipped from Minneapolis/Saint Paul, Minnesota, to Columbus, Ohio, and back to Minneapolis/Saint Paul, under warm, monitored temperatures. Products underwent quality control (QC) testing including cell count, immunophenotyping, viability, endotoxin, sterility culture, and cytotoxicity assays. One product tested the relative importance of IL-2 and controlled incubation.

RESULTS: The length of shipment ranged from 14 to 16 hours, and temperatures were well controlled. QC testing was acceptable based upon previous in-house experience. Controlled incubation was not necessary for successful activation of NK cells, but IL-2 appeared essential.

CONCLUSION: The need for novel cell therapies to be infused as fresh products may be a limitation for various cell types. However, we have shown that NK cells can be successfully shipped in the fresh state (allowing 48 hr from apheresis to product infusion) for use at clinical centers. Although IL-2 is critical for NK-cell activation, a 37°C, 5% CO2 incubator is not.

Get access to the full text of this article

Ancillary